← Leaderboards
Jianguo Liu
Saint Louis University
$5,226,779
Attributed
$6,561,967
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,561,967 · 8
By mechanism
R01$4,198,614 · 2
R21$1,630,863 · 4
K22$514,937 · 1
R03$217,553 · 1
Top collaborators
- Daniel F. Hoft4 shared
Most similar at Saint Louis University
Same institution · by research overlap
- Daniel F. Hoft$50,608,486
- Daniel Hoft$14,766,530
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingMacrophageInflammationCellsMolecularProteinsCytokineMessenger RnaGrowthKnockout MiceInflammatoryProductionInflammatory ResponsePlayLungMalignant Breast NeoplasmNeoplasm MetastasisTnf GeneMammary NeoplasmsChemokineBreast Cancer TreatmentArthritisIn VivoTumor
Grant awards (23)
Th9 cells and protective TB immunity$667,594
R01 · FY2025 · AI
Th9 cells and protective TB immunity$667,594
R01 · FY2024 · AI
Th9 cells and protective TB immunity$667,594
R01 · FY2023 · AI
Role of RNA-binding protein in immune evasion of Mtb in macrophages$227,250
R21 · FY2023 · AI · contact PI
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer$211,736
R21 · FY2023 · CA · contact PI
Th9 cells and protective TB immunity$667,594
R01 · FY2022 · AI
Role of RNA-binding protein in immune evasion of Mtb in macrophages$189,375
R21 · FY2022 · AI · contact PI
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer$186,877
R21 · FY2022 · CA · contact PI
A new target for host-directed therapy against TB infection$189,375
R21 · FY2021 · AI · contact PI
A new target for host-directed therapy against TB infection$227,250
R21 · FY2020 · AI · contact PI
The role of tristetraprolin in control of breast cancer progression$311,250
R01 · FY2016 · CA · contact PI
The role of tristetraprolin in control of breast cancer progression$311,250
R01 · FY2015 · CA · contact PI
The role of tristetraprolin in control of breast cancer progression$301,913
R01 · FY2014 · CA · contact PI
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus$187,500
R21 · FY2014 · AI · contact PI
The role of tristetraprolin in control of breast cancer progression$292,575
R01 · FY2013 · CA · contact PI
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus$211,500
R21 · FY2013 · AI · contact PI
The role of tristetraprolin in control of breast cancer progression$311,250
R01 · FY2012 · CA · contact PI
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth$172,799
K22 · FY2012 · CA · contact PI
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth$172,799
K22 · FY2011 · CA · contact PI
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms$70,478
R03 · FY2011 · AR · contact PI
Molecular mechanisms of host-derived CCL5 mediated mammary tumor growth$169,339
K22 · FY2010 · CA · contact PI
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms$73,325
R03 · FY2010 · AR · contact PI
PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms$73,750
R03 · FY2009 · AR · contact PI